The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Half-yearly Report

31 Mar 2008 08:00

31 March 2008 Sterling Green Group plc ("the Group" or "the Company") Second Interim Results for the six months ended 31 December 2007

CHAIRMAN'S STATEMENT

Introduction

As envisaged at the time of the publication of the AIM Admission document in April 2007, the Company's accounting reference date was changed to 31 March and accordingly the audited financial statements will cover the 15 month period from 1 January 2007 to 31 March 2008.

In this statement, the financial information covers the unaudited second interim results of the Group for 2007 which covers the period from 1 July 2007 to 31 December 2007.

Results and dividends

The Group generated an unaudited loss before tax for the six month period of ‚£ 895,000 (six months to 30 June 2007 - ‚£318,000 loss) on turnover of ‚£702,000 (six months to 30 June 2007 - ‚£150,000). The Directors do not recommend the payment of a dividend for the period.

The Group had three trading subsidiaries operating during the period, Sterling Green Limited ("SGL"), Sterling Green Mortgages Limited ("SGM") and TaxDebts Limited ("Tax Debts"), which commenced trading in the period. The Group currently provides debt management services through SGL, advice relating to consolidation loans and mortgages through SGM, and personal tax debt payment solutions through Tax Debts.

Outlook

The Board is implementing its strategy of creating a financial services group which offers a wide range of financial solutions to members of the general public who, for a number of reasons, may have over extended themselves with respect to levels of personal indebtedness.

The level of debt issues facing a large proportion of the UK general public is receiving significant coverage in the media. The Board believes that the credit crunch affecting the money markets recently will increase the number of potential clients who could benefit from the services provided by the Group in the medium term and several partnerships have been signed or are in the pipeline which could also lead to an increased number of potential clients being passed onto us. As a result, the Board is looking forward to 2008 with the feeling that it is well placed to offer a comprehensive range of financial solutions to assist the growing number of people who are experiencing problems relating to the level of their personal debt. On the downside, mortgages have become very much more difficult to obtain for clients because of the recent well publicised financial problems and this is likely to result in slower growth in this area until the market settles.

Having recently raised ‚£750,000 before costs for working capital purposes, the Board remains optimistic that the Group will be able to generate growth and enhance shareholder value in the medium term.

Michael EdelsonChairman31 March 2008

CONSOLIDATED INCOME STATEMENT

FOR THE SIX MONTH PERIOD ENDED 31 DECEMBER 2007

Six months Six months Year ended ended ended 31 December 30 June 31 December 2007 2007 2006 (Unaudited) (Unaudited) (Audited) ‚£000 ‚£000 ‚£000 Revenue 702 150 - Cost of sales (748) (155) - Gross loss (46) (5) - Administrative expenses (840) (329) (75) Operating loss (886) (334) (75) Investment income 4 16 2 Finance costs (13) - - Loss on ordinary activities before (895) (318) (73)taxation Income tax expense - - - Loss on ordinary activities after (895) (318) (73)taxation Loss per share - basic and diluted (0.36)p (0.16)p (0.13)pCONSOLIDATED BALANCE SHEETAS AT 31 DECEMBER 2007 31 December 30 June 31 December 2007 2007 2006 (Unaudited) (Unaudited) (Audited) ‚£000 ‚£000 ‚£000 ASSETS Non-current assets Property, plant and equipment 330 355 - Goodwill 1,078 1,078 - Total non-current assets 1,408 1,433 - Current assets Trade and other receivables 138 159 27 Cash and cash equivalents 167 443 61 Total current assets 305 602 88 LIABILITIES Current liabilities Trade and other payables (495) (228) (72) Net current (liabilities)/assets (190) 374 16 Total assets less current 1,218 1,807 16liabilities Non-current liabilities Trade and other payables (175) (219) - Net assets 1,043 1,588 16 EQUITY Share capital 250 250 85 Share capital to be issued 350 - - Share premium account 834 834 - Capital reserve 6 6 6 Other reserves 891 891 - Retained losses (1,288) (393) (75) Total equity 1,043 1,588 16

CONSOLIDATED CASH FLOW STATEMENT

FOR THE SIX MONTH PERIOD ENDED 31 DECEMBER 2007

Six months Six months Year ended ended ended 31 December 30 June 31 December 2007 2007 2006 (Unaudited) (Unaudited) (Audited) ‚£000 ‚£000 ‚£000 Cash flows from operating activities Loss before tax (895) (318) (73) Adjustments for: Depreciation 63 18 - Investment income (4) (16) (2) Finance costs 13 - - Share based payment charge - - 6 Decrease/(increase) in trade and 21 (40) (27)other receivables Increase/(decrease) in trade and 267 (94) 68other payables Cash outflow from operating (535) (450) (28)activities Finance costs paid (13) - - Net cash used in operating (548) (450) (28)activities Cash flows from investing activities Acquisition of subsidiary, net of - (152) -cash acquired Purchase of property, plant and (38) (339) -equipment Investment income received 4 16 2 Net cash (used in)/from investing (34) (475) 2activities Cash flows from financing activities Capital element of finance lease (44) (2) -payments Finance leases entered into - 307 - Proceeds in advance of issue of 350 - -share capital Proceeds from issue of share capital - 1,002 35 Net cash from financing activities 306 1,307 35 Net (decrease)/increase in cash and (276) 382 9cash equivalents Cash and cash equivalents at 443 61 52beginning of period Cash and cash equivalents at end of 167 443 61period

STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTH PERIOD ENDED 31 DECEMBER 2007

Share Share Share Capital Other Retained Total capital capital reserve reserves losses to be premium issued account ‚£000 ‚£000 ‚£000 ‚£000 ‚£000 ‚£000 ‚£000 Balance at 1 January 50 - - - - (2) 482006 Loss for the year - - - - - (73) (73) Issue of share 35 - - - - - 35capital Share based payments - - - 6 - - 6 Balance at 1 January 85 - - 6 - (75) 162007 Loss for the period - - - - - (318) (318) Issue of share 165 - 957 - 891 - 2,013capital Share issue costs - - (123) - - - (123) Balance at 30 June 250 - 834 6 891 (393) 1,5882007 Loss for the period - - - - - (895) (895) Share capital to be - 350 - - - - 350issued Balance at 31 250 350 834 6 891 (1,288) 1,043December 2007

NOTES TO THE INTERIM REPORT

FOR THE SIX MONTH PERIOD ENDED 31 DECEMBER 2007

1. The interim financial statements have not been audited and they do not

constitute full financial statements within the meaning of s240 of the

Companies Act 1985. The statutory accounts for the year ended 31 December

2006 have been delivered to the Registrar of Companies. The auditors'

opinion on those accounts was unqualified and did not contain a statement

under s237(2) or s237(3) of the Companies Act 1985.

2. The next accounting reference date will be 31 March 2008 and financial statements for this period will be prepared in accordance with International Financial Reporting Standards (IFRS) as required by European Law. The interim financial statements have been prepared in accordance with accounting policies that are expected to apply to the financial statements for the period ending 31 March 2008.

3. Basic loss per share has been calculated using a loss for the period of ‚£ 895,000 (‚£318,000 loss for the six month period ended 30 June 2007 and ‚£73,000 loss for the year ended 31 December 2006) and a weighted average number of ordinary shares in issue during the six month period ended 31 December 2007 of 249,675,390 (202,148,621 for the six month period ended 30 June 2007 and 55,833,333 for the year ended 31 December 2006).

Diluted loss per share is calculated by adjusting the weighted average number of ordinary shares in issue assuming conversion of all dilutive potential ordinary shares. The Company's potential ordinary shares consist of share options and deferred consideration shares. Due to the loss in the current and comparative periods there are no dilutive ordinary shares.

4. Goodwill arising on the acquisition of Sterling Green Limited on 27 April

2007 amounting to ‚£1,078,000 has been capitalised.

Goodwill has been calculated on the basis of initial consideration. Deferred consideration may become payable up to a maximum of ‚£1,050,000 but this cannot be assessed as probable at this stage. If additional consideration becomes payable, the value of goodwill will change accordingly. Any deferred consideration payable will be satisfied by the issue of up to 65,625,000 new ordinary shares in the Company. The calculation of additional consideration payable is based on certain revenue and EBITDA targets for the two years ending 31 March 2009.

The Group has taken advantage of s131 of the Companies Act 1985 and has credited the share premium arising on the acquisition of Sterling Green Limited to other reserves.

5. In December 2007 the Company received ‚£350,000 in advance of the issue of

new ordinary shares. Accordingly, this amount has been shown as an equity

balance at 31 December 2007 under the heading `'share capital to be

issued'. Subsequent to the balance sheet date, the ‚£350,000 received has

been allocated as to ‚£14,000 share capital and ‚£336,000 share premium.

On 4 January 2008 the Company issued 22,000,000 new ordinary shares at a price of 2.5 pence per share. On 7 February, the Company issued a further 8,000,000 new ordinary shares at a price of 2.5 pence per share

6. Copies of the Interim Report can be obtained by writing to The Company Secretary, Sterling Green Group plc, Number 14, The Embankment, Vale Road, Heaton Mersey, Stockport, Cheshire SK4 3GN. Alternatively, copies can also be downloaded from the Company's website which is www.sterlinggreen.co.uk.

Further enquiries:Sterling Green Group plc Michael Edelson Tel: 0161 975 0434 John East & Partners Limited David Worlidge/Simon Clements Tel: 020 7628 2200

STERLING GREEN GROUP PLC
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.